# EDGAR Filing Document

**Accession Number:** 0001837607
**File Stem:** 0001837607-25-000059
**Filing Date:** 2025-6
**Character Count:** 5911
**Document Hash:** d1bed8e75baaf81a3c09e287e9097369
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001837607-25-000059.hdr.sgml**: 20250613

**ACCESSION NUMBER**: 0001837607-25-000059

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250613

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250613

**DATE AS OF CHANGE**: 20250613

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AEON Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0001837607
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 853940478
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40021
- **FILM NUMBER:** 251046441

**BUSINESS ADDRESS:**
- **STREET 1:** 5 PARK PLAZA
- **STREET 2:** SUITE 1750
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614
- **BUSINESS PHONE:** (949) 354-6499

**MAIL ADDRESS:**
- **STREET 1:** 5 PARK PLAZA
- **STREET 2:** SUITE 1750
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Priveterra Acquisition Corp.
- **DATE OF NAME CHANGE:** 20201222

?xml version='1.0' encoding='ASCII'? AEON Biopharma, Inc._June 13, 2025

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 13, 2025**

## AEON Biopharma, Inc.
**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40021** | **85-3940478** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification Number)** |

---

**5 Park Plaza**

**Suite 1750**

**Irvine, CA 92614**

**(Address of principal executive offices, including Zip Code)**

**Registrant's telephone number, including area code: (949) 354-6499**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Class A Common Stock, $0.0001 par value per share | AEON | NYSE American |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp; ☐

------

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

AEON Biopharma, Inc. (the "Company") held its Annual Meeting of Stockholders on June 13, 2025 (the "Annual Meeting") as described in the Company's proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission (the "SEC") on April 29, 2025, as supplemented with materials filed with the SEC on June 11, 2025 (the "2025 Proxy"). At the Annual Meeting, the stockholders of the Company voted on two proposals as further described in the 2025 Proxy. The final results for each proposal voted on by the stockholders at the Annual Meeting, as certified by the Company's inspector of elections, are set forth below.

Proposal 1: The stockholders of the Company elected each of Jost Fischer and Eric Carter as Class II directors of the Company's board of directors (the "Class II Directors") for a three-year term ending at the Annual Meeting of Stockholders to be held in 2028 and until each of their successors has been duly elected and qualified. The voting results with respect to the election of the Class II Directors were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Nominee** | &nbsp;&nbsp;**Term Expiring** | &nbsp;&nbsp;**For** | &nbsp;&nbsp;**Withheld** | &nbsp;&nbsp;**Broker Non-Vote** |
| &nbsp;&nbsp;Jost Fischer | &nbsp;&nbsp;2028 | &nbsp;&nbsp;661774 | &nbsp;&nbsp;138295 | &nbsp;&nbsp;4357218 |
| &nbsp;&nbsp;Eric Carter | &nbsp;&nbsp;2028 | &nbsp;&nbsp;674894 | &nbsp;&nbsp;125175 | &nbsp;&nbsp;4357218 |

---

Proposal 2: The stockholders of the Company ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ended December 31, 2025. The voting results for this proposal were as follows:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**For** | &nbsp;&nbsp;**Against** | &nbsp;&nbsp;**Abstain** | &nbsp;&nbsp;**Broker Non-Vote** |
| &nbsp;&nbsp;4,956,438 | &nbsp;&nbsp;170,672 | &nbsp;&nbsp;30,177 | &nbsp;&nbsp;- |

---

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **AEON Biopharma, Inc.** | **AEON Biopharma, Inc.** |
| Date: June 13, 2025 | By: | /s/ Robert Bancroft |
|  |  | Robert Bancroft |
|  |  | Chief Executive Officer |

---